168 related articles for article (PubMed ID: 10181074)
1. Atypical antipsychotics in the managed care era.
Loebel AD; Botts SR; Feldman BI
Am J Manag Care; 1998 Jan; 4 Suppl():S37-50; quiz S51-2. PubMed ID: 10181074
[TBL] [Abstract][Full Text] [Related]
2. Methods of cost-effectiveness analysis in the evaluation of new antipsychotics: implications for schizophrenia treatment.
Neumann PJ
J Clin Psychiatry; 1999; 60 Suppl 3():9-14; discussion 15. PubMed ID: 10073371
[TBL] [Abstract][Full Text] [Related]
3. The rate, pattern, and cost of use of antiparkinsonian agents among patients treated for schizophrenia in a managed care setting.
Ascher-Svanum H; Kennedy JS; Lee D; Haberman M
Am J Manag Care; 2004 Jan; 10(1):20-4. PubMed ID: 14738183
[TBL] [Abstract][Full Text] [Related]
4. Effectiveness and cost of atypical versus typical antipsychotic treatment for schizophrenia in routine care.
Stargardt T; Weinbrenner S; Busse R; Juckel G; Gericke CA
J Ment Health Policy Econ; 2008 Jun; 11(2):89-97. PubMed ID: 18509216
[TBL] [Abstract][Full Text] [Related]
5. Outcome in schizophrenia: beyond symptom reduction.
Meltzer HY
J Clin Psychiatry; 1999; 60 Suppl 3():3-7; discussion 8. PubMed ID: 10073370
[TBL] [Abstract][Full Text] [Related]
6. Antipsychotic safety and efficacy concerns.
Meyer JM
J Clin Psychiatry; 2007; 68 Suppl 14():20-6. PubMed ID: 18284274
[TBL] [Abstract][Full Text] [Related]
7. The cost of schizophrenia.
Wasylenki DA
Can J Psychiatry; 1994 Nov; 39(9 Suppl 2):S65-9. PubMed ID: 7874667
[TBL] [Abstract][Full Text] [Related]
8. Annual health outcomes and treatment costs for schizophrenia populations.
Mauskopf JA; David K; Grainger DL; Gibson PJ
J Clin Psychiatry; 1999; 60 Suppl 19():14-9; discussion 20-2. PubMed ID: 10507276
[TBL] [Abstract][Full Text] [Related]
9. A pharmacoeconomic analysis of atypical antipsychotics and haloperidol in first-episode schizophrenic patients in taiwan.
Gau SS; Chung CH; Gau CS
J Clin Psychopharmacol; 2008 Jun; 28(3):271-8. PubMed ID: 18480683
[TBL] [Abstract][Full Text] [Related]
10. Access to atypical antipsychotics: a public payor's perspective.
Haveman JK
Behav Healthc Tomorrow; 1998 Aug; 7(4):45-8. PubMed ID: 10182153
[No Abstract] [Full Text] [Related]
11. Formulary decisions and health economics.
Glazer WM
J Clin Psychiatry; 1998; 59 Suppl 19():23-9. PubMed ID: 9847049
[TBL] [Abstract][Full Text] [Related]
12. Treatment of schizophrenia: let's talk dollars and sense.
Buckley PF
Am J Manag Care; 1998 Mar; 4(3):369-83. PubMed ID: 10178499
[TBL] [Abstract][Full Text] [Related]
13. Review of the evidence for the long-term efficacy of atypical antipsychotic agents in the treatment of patients with schizophrenia and related psychoses.
Turner MS; Stewart DW
J Psychopharmacol; 2006 Nov; 20(6 Suppl):20-37. PubMed ID: 17046985
[TBL] [Abstract][Full Text] [Related]
14. Methods of pharmacoeconomic evaluation of psychopharmacologic therapies for patients with schizophrenia.
Revicki DA
J Psychiatry Neurosci; 1997 Jul; 22(4):256-66. PubMed ID: 9262048
[TBL] [Abstract][Full Text] [Related]
15. Are the second-generation antipsychotics cost-effective? A critical review on the background of different health systems.
Hamann J; Leucht S; Kissling W
Pharmacopsychiatry; 2003 Jan; 36(1):18-26. PubMed ID: 12649770
[TBL] [Abstract][Full Text] [Related]
16. In the aftermath of CATIE: how should administrators value atypical antipsychotic medications?
Luchins DJ
Adm Policy Ment Health; 2006 Sep; 33(5):541-3. PubMed ID: 16688482
[TBL] [Abstract][Full Text] [Related]
17. [Consumption and cost of antipsychotic drugs].
Pérez J; Marín N; Vallano A; Castells X; Capellà D
Actas Esp Psiquiatr; 2005; 33(2):110-6. PubMed ID: 15768318
[TBL] [Abstract][Full Text] [Related]
18. Randomized controlled trial of the effect on Quality of Life of second- vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1).
Jones PB; Barnes TR; Davies L; Dunn G; Lloyd H; Hayhurst KP; Murray RM; Markwick A; Lewis SW
Arch Gen Psychiatry; 2006 Oct; 63(10):1079-87. PubMed ID: 17015810
[TBL] [Abstract][Full Text] [Related]
19. Cost analysis of treating schizophrenia with amisulpride: naturalistic mirror image study.
Surguladze S; Patel A; Kerwin RW; Knapp M; Travis MJ
Prog Neuropsychopharmacol Biol Psychiatry; 2005 May; 29(4):517-22. PubMed ID: 15866352
[TBL] [Abstract][Full Text] [Related]
20. Perspective and the measurement of costs and benefits for cost-effectiveness analysis in schizophrenia.
Meltzer D
J Clin Psychiatry; 1999; 60 Suppl 3():32-5; discussion 36-7. PubMed ID: 10073375
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
